Free Trial
NASDAQ:AUXL

Auxilium Pharmaceuticals (AUXL) Stock Price, News & Analysis

→ Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad)
Free AUXL Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
1.32 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
AUXL stock logo

About Auxilium Pharmaceuticals Stock (NASDAQ:AUXL)

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

AUXL Stock News Headlines

April 17, 2024 | tmcnet.com
Elevated Signals and Auxilium Partner to Recover the $3.4 Trillion of Critical Minerals in Mining Waste
January 1, 2024 | investing.com
AUX/ETH - Auxilium Ethereum
April 25, 2024 | Behind the Markets (Ad)
The World's First "$20 Trillion Drug?"
One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!
September 14, 2023 | investing.com
AUX/USD - Auxilium US Dollar
April 22, 2023 | dailymail.co.uk
'Male menopause is a myth'
November 19, 2022 | finance.yahoo.com
Marine Pharmaceuticals Market to grow by USD 1.56 Bn; Oncology to be the largest revenue generating segment - Technavio
September 13, 2022 | thestreet.com
Why Auxilium Pharmaceutical (AUXL) Stock Is Down This Morning
August 27, 2022 | thestreet.com
Auxilium Pharmaceuticals' Slow Response to Endo Troubles Investors
See More Headlines
Receive AUXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auxilium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2014
Today
4/25/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AUXL
CUSIP
05334D10
CIK
1182129
Web
www.auxilium.com
Phone
+1-484-3215900
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

AUXL Stock Analysis - Frequently Asked Questions

How were Auxilium Pharmaceuticals' earnings last quarter?

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) issued its quarterly earnings data on Thursday, October, 30th. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.30. The biopharmaceutical company had revenue of $109.60 million for the quarter, compared to analyst estimates of $101.02 million. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 earnings per share.

What other stocks do shareholders of Auxilium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Auxilium Pharmaceuticals investors own include Royalty Pharma (RPRX), Yelp (YELP), AEGR (AEGR), Arctos NorthStar Acquisition (ANAC), MannKind (MNKD), Netflix (NFLX), Acorda Therapeutics (ACOR), Altaba (AABA), Agios Pharmaceuticals (AGIO) and Allergan (AGN).

This page (NASDAQ:AUXL) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
These AI trades triggered this morning (545% return)
Prosper Trading Academy
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
He Is Giving Away Bitcoin
Crypto Swap Profits
Fed launches fourth dollar overhaul
Stansberry Research
The only accurate crypto trading system I know …
Weiss Ratings
Bitcoin Rockets To Record High But Buy THIS Instead
Paradigm Press